dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Alanine/serine/cysteine transporter subfamily (type: transporter)
Target: Alanine/serine/cysteine transporter 2

Ligand: benzylcysteine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 3.109999895095825 pKi
Reference (Journal): New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak.
Published in: J Physiol (Lond.)

Ligand: compound 25e [PMID: 38217503] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.289999961853027 pIC50
Reference (Journal): Discovery of Novel Aminobutanoic Acid-Based ASCT2 Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Published in: J Med Chem

Ligand: p-nitrophenyl glutamyl anilide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.260000228881836 pKi
Reference (Journal): Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site.
Published in: Bioorg Med Chem

Ligand: benzylserine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 3.049999952316284 pKi
Reference (Journal): New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak.
Published in: J Physiol (Lond.)
Target family: Alpha subfamily (type: enzyme)
Target: protein kinase C gamma

Ligand: Ro-32-0432 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C.
Published in: Biochem J

Ligand: ruboxistaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
Published in: J Med Chem
Target family: Alpha subfamily (type: enzyme)
Target: protein kinase C beta

Ligand: Ro-32-0432 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C.
Published in: Biochem J

Ligand: Ro-32-0432 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation.
Published in: J Pharmacol Exp Ther

Ligand: ruboxistaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.229999542236328 pIC50
Reference (Journal): (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
Published in: J Med Chem

Ligand: sotrastaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
Published in: J Med Chem
Target family: Alpha subfamily (type: enzyme)
Target: protein kinase C gamma

Ligand: 10-Me-Aplog-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 8.260000228881836 pKi
Reference (Journal): Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.
Published in: J Med Chem

Ligand: 7-hydroxystaurosporine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Published in: Mol Pharmacol

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A.
Published in: J Med Chem

Ligand: enzastaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.
Published in: Bioorg Med Chem Lett

Ligand: GF109203X (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
Published in: J Biol Chem

Ligand: Gö 6983 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes.
Published in: FEBS Lett

Ligand: ingenol mebutate (Natural product)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA & EMA (2012)
Primary target: no
Median affinity: 9.789999961853027 pKi
Reference (Journal): Characterization of the interaction of ingenol 3-angelate with protein kinase C.
Published in: Cancer Res

Ligand: Ro-32-0432 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation.
Published in: J Pharmacol Exp Ther
Target family: Amino acid hydroxylases (type: enzyme)
Target: L-Tyrosine hydroxylase

Ligand: methyltyrosine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity:  -
Target family: Amino acid hydroxylases (type: enzyme)
Target: L-Tryptophan hydroxylase 2

Ligand: 6-fluorotryptophan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): (+)-6-fluorotryptophan, an inhibitor of tryptophan hydroxylase: sleep and wakefulness in the rat.
Published in: Neuropharmacology
Target family: Amino acid hydroxylases (type: enzyme)
Target: L-Phenylalanine hydroxylase

Ligand: α-methylphenylalanine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Alpha-methylphenylalanine, a new inducer of chronic hyperphenylalaninemia in sucling rats.
Published in: Science

Ligand: fenclonine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: sapropterin (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2007), EMA (2008)
Primary target: yes
Median affinity: 5.400000095367432 pKi
Reference (Journal): Tetrahydrobiopterin binding to aromatic amino acid hydroxylases. Ligand recognition and specificity.
Published in: J Med Chem
Target family: Amino acid hydroxylases (type: enzyme)
Target: L-Tryptophan hydroxylase 2

Ligand: α-propyldopacetamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: fenclonine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: fenfluramine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2020)
Median affinity:  -

Ligand: rodatristat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: TPT-004 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors
Published in: J Med Chem
Target family: Amino acid hydroxylases (type: enzyme)
Target: L-Tyrosine hydroxylase

Ligand: 3-chlorotyrosine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: 3-iodotyrosine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: alpha-methyltyrosine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity:  -

Ligand: α-propyldopacetamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Aminoacyl-tRNA synthetases (type: other_protein)
Target: Plasmodium falciparum lysyl-tRNA synthetase

Ligand: compound 5 [PMID: 30894487] (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.289999961853027 pEC50
Reference (Journal): Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.
Published in: Proc Natl Acad Sci USA
Target family: Aminoacyl-tRNA synthetases (type: other_protein)
Target: Plasmodium falciparum phenylalanyl-tRNA synthetase alpha subunit

Ligand: BRD3444 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.340000152587891 pIC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD3444 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.849999904632568 pEC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD3444 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.179999828338623 pEC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD3444 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pEC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD7929 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pEC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD7929 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD7929 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.789999961853027 pEC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature

Ligand: BRD7929 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pEC50
Reference (Journal): Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
Published in: Nature
Target family: Aminoacyl-tRNA synthetases (type: other_protein)
Target: Plasmodium falciparum threonyl-tRNA synthetase

Ligand: borrelidin (Natural product)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.739999771118164 pIC50
Reference (Journal): In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia.
Published in: J Antibiot (Tokyo)

Ligand: borrelidin (Natural product)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.90999984741211 pIC50
Reference (Journal): Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.
Published in: Proc Natl Acad Sci U S A

Ligand: borrelidin (Natural product)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pIC50
Reference (Journal): In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia.
Published in: J Antibiot (Tokyo)
Target family: Aminoacyl-tRNA synthetases (type: other_protein)
Target: Plasmodium falciparum tryptophanyl-tRNA synthetase

Ligand: indolmycin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.769999980926514 pIC50
Reference (Journal): Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death in Plasmodium falciparum.
Published in: Sci Rep
Target family: Aminoacyl-tRNA synthetases (type: other_protein)
Target: Plasmodium falciparum threonyl-tRNA synthetase

Ligand: borrelidin (Natural product)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.010000228881836 pIC50
Reference (Journal): Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.
Published in: Proc Natl Acad Sci U S A
Target family: Aminoacyl-tRNA synthetases (type: other_protein)
Target: Plasmodium falciparum isoleucyl-tRNA synthetase

Ligand: mupirocin (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1987), UK (1998)
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Journal): Validation of isoleucine utilization targets in Plasmodium falciparum.
Published in: Proc Natl Acad Sci U S A
Target family: AMPK subfamily (type: enzyme)
Target: protein kinase AMP-activated non-catalytic subunit beta 2

Ligand: MT47-100 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 4.610000133514404 pKi
Reference (Journal): Inhibition of AMP-Activated Protein Kinase at the Allosteric Drug-Binding Site Promotes Islet Insulin Release.
Published in: Chem Biol
Target family: AMPK subfamily (type: enzyme)
Target: protein kinase AMP-activated non-catalytic subunit beta 1

Ligand: MT47-100 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 5.429999828338623 pKi
Reference (Journal): Inhibition of AMP-Activated Protein Kinase at the Allosteric Drug-Binding Site Promotes Islet Insulin Release.
Published in: Chem Biol
Target family: AMPK subfamily (type: enzyme)
Target: AMP kinase

Ligand: dorsomorphin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.389999866485596 pIC50
Reference (Journal): The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: compound 13a [PMID: 23639540] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Published in: Bioorg Med Chem Lett

Ligand: cerdulatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Journal): The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Published in: J Pharmacol Exp Ther

Ligand: adenosine 5'-monophosphate (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 4.210000038146973 pEC50
Reference (Journal): Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Published in: Cell Metab

Ligand: acadesine (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -
Reference (Journal): 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?
Published in: Eur J Biochem

Ligand: A-769662 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 6.150000095367432 pEC50
Reference (Journal): Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Published in: Cell Metab

Ligand: A-769662 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pEC50
Reference (Journal): Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.
Published in: Cell Metab

Ligand: A-769662 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 6.940000057220459 pEC50
Reference (Journal): Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase.
Published in: J Biol Chem
Target family: Angiotensin receptors (type: gpcr)
Target: AT<sub>1</sub> receptor

Ligand: ZD-7155 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.420000076293945 pIC50
Reference (Journal): Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Published in: J Med Chem
Target family: Aquaporins (type: other_ic)
Target: AQP3

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Primary target: no
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP0

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP1

Ligand: 5-Hydroxymethyl-2-furfural (Natural product)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.369999885559082 pIC50
Reference (Journal): 5-Hydroxymethyl-Furfural and Structurally Related Compounds Block the Ion Conductance in Human Aquaporin-1 Channels and Slow Cancer Cell Migration and Invasion.
Published in: Mol Pharmacol

Ligand: Ag+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -

Ligand: compound 1 [PMID: 23113556] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.099999904632568 pIC50
Reference (Journal): Discovery of novel human aquaporin-1 blockers.
Published in: ACS Chem Biol

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -

Ligand: pCMBS (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP10

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP2

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP3

Ligand: Audien (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 4.769999980926514 pIC50
Reference (Journal): Targeting aquaporin function: potent inhibition of aquaglyceroporin-3 by a gold-based compound.
Published in: PLoS ONE

Ligand: Auphen (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Targeting aquaporin function: potent inhibition of aquaglyceroporin-3 by a gold-based compound.
Published in: PLoS ONE
Target family: Aquaporins (type: other_ic)
Target: AQP5

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP6

Ligand: Hg2+ (Inorganic)
Interaction type: Activator
Action: None
Primary target: no
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP7

Ligand: Auphen (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP8

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -
Target family: Aquaporins (type: other_ic)
Target: AQP9

Ligand: Hg2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Median affinity:  -

Ligand: phloretin (Natural product)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Arginase (type: enzyme)
Target: Arginase I

Ligand: compound 9 [PMID: 23472952] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.650000095367432 pIC50
Reference (Journal): Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury.
Published in: J Med Chem
Target family: Arginase (type: enzyme)
Target: Arginase II

Ligand: 2(S)-amino-6-boronohexanoic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.069999694824219 pKi
Reference (Journal): Classical and slow-binding inhibitors of human type II arginase.
Published in: Biochemistry

Ligand: compound 9 [PMID: 23472952] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.289999961853027 pIC50
Reference (Journal): Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury.
Published in: J Med Chem